Zheng Feng Chee
Contributor since: 2017
Turkcell: Excellent Business Hampered By Politics
Activision: Attractive Arbitrage Opportunity
Educational Development Corporation: Short-Term Pain, Long-Term Gain
Educational Development Corporation: Turning Inventory Into Cash Flow
Endo International: The End May Be Near
Educational Development Corporation: An Undervalued Growing Cash Generator
Educational Development Corp.: A Value Gem
Mallinckrodt: Bankruptcy Finalized
Mallinckrodt: It's Your Move
Mallinckrodt: A Series Of Unfortunate Events
TherapeuticsMD: Hanging On A Thread
Mallinckrodt: Back To The Negotiating Table
Mallinckrodt: Last Ditch Attempt By CMS
Mallinckrodt: A Complex Transaction Signaling A New Beginning
Mallinckrodt: It's All In The Posture
TherapeuticsMD: Q2 Earnings Review
TherapeuticsMD: Buy Before Earnings Trading Idea
TherapeuticsMD: Dilution Risk Overblown
Mallinckrodt: Lawsuit Worries Massively Overblown
Mallinckrodt: One-Year Review
TherapeuticsMD: The Future Still Looks Bright
TherapeuticsMD: Execution, Execution, Execution
TherapeuticsMD: What's Up With The Recent Insider Sales?
TherapeuticsMD: Licensing, Partnership, And Dilution, What Is Happening?
TherapeuticsMD: More Room To Grow?
Are The Shorts Right About Mallinckrodt?
TherapeuticsMD: Debt Financing Delay
Mallinckrodt: Substantial Upside
CD Projekt: The Price Is Not Right
Will Apple Buy Netflix?
TherapeuticsMD: Class 2 Re-Submission Is Not The End Of The World
Is TherapeuticsMD Overvalued?
TherapeuticsMD: Will TX-004HR Be A Blockbuster?
TherapeuticsMD's Dilution Fear Is Overdone
The Road Ahead For TherapeuticsMD
An Irrational Reaction To TherapeuticsMD's News Release
Profit From TherapeuticsMD's Upcoming FDA Catalyst